# Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

> **NCT04070157** · PHASE2 · TERMINATED · sponsor: **USWM, LLC (dba US WorldMeds)** · enrollment: 4 (actual)

## Conditions studied

- Opioid Withdrawal (Disorder)

## Interventions

- **DRUG:** Lofexidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04070157
- **Lead sponsor:** USWM, LLC (dba US WorldMeds)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-02
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** COVID pandemic and enrollment issues necessitating an adjustment to the study design.
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070157, "Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04070157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*